Evotec SE (EVO) Non-Current Assets (2009 - 2026)
Evotec SE (EVO) reported Non-Current Assets of $1.1 million for Q1 2026, down 15.36% on a YoY basis from $1.3 million in Q1 2025, and down 1.8% sequentially from $1.1 million in Q4 2025.
Evotec SE (EVO) Non-Current Assets (2009 - 2026) Analysis & Trends
Evotec SE (EVO) has 9 years of Non-Current Assets data on file, last reported at $1.1 million in Q1 2026.
- For the quarter ending Q1 2026, Non-Current Assets fell 15.36% year-over-year to $1.1 million; the trailing twelve-month figure through Mar 2026 stood at $1.1 million (down 15.36% YoY), and the FY2025 full-year result was $1.1 million, down 99.91% from the prior year.
- Non-Current Assets retreated to $1.1 million in Q1 2026, from $1.1 million in the prior quarter.
- In the past five years, Non-Current Assets ranged from a high of $1.3 billion in Q4 2023 to a low of $1.1 million in Q1 2026.
- A 5-year average of $302.6 million and a median of $1.3 million in 2025 frame the typical range for Non-Current Assets.
- Across the five-year window, Non-Current Assets advanced 21.02% in 2023 and plunged 99.91% in 2025, its largest moves.
- Tracing EVO's Non-Current Assets over 5 years: stood at $1.1 billion in 2022, then gained by 21.02% to $1.3 billion in 2023, then decreased by 1.37% to $1.3 billion in 2024, then slumped by 99.91% to $1.1 million in 2025, then declined by 1.8% to $1.1 million in 2026.
- Business Quant data shows EVO's Non-Current Assets at $1.1 million in Q1 2026, $1.1 million in Q4 2025, and $1.1 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | 36.78 Bn |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 26.33 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 8.68 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 79.20 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 3.84 Bn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | 15.70 Bn |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 25.92 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 2.47 Bn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 9.64 Bn |
| 10 | Evotec SE | 351.60 Mn | 351.08 Mn | - | 1.09 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.09 Mn |
| Dec 31, 2025 | 1.11 Mn |
| Sep 30, 2025 | 1.15 Mn |
| Jun 30, 2025 | 1.36 Mn |
| Mar 31, 2025 | 1.28 Mn |
| Dec 31, 2024 | 1.27 Bn |
| Sep 30, 2024 | 1.42 Mn |
| Mar 31, 2024 | 1.50 Mn |
| Dec 31, 2023 | 1.29 Bn |
| Dec 31, 2022 | 1.06 Bn |
| Sep 30, 2022 | 1.18 Mn |
| Mar 31, 2022 | 1.26 Mn |
| Dec 31, 2021 | 970.17 Mn |
| Sep 30, 2021 | 1.34 Mn |
| Dec 31, 2020 | 898.44 Mn |
| Sep 30, 2010 | 125,722.18 |
| Jun 30, 2010 | 90,917.59 |
| Mar 31, 2010 | 108.58 |
| Dec 31, 2009 | 114,656.60 |
| Jun 30, 2009 | 114.84 Mn |